Jun Hirai
Overview
Explore the profile of Jun Hirai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanai Y, Hirai J, Kobayashi M, Matsuo K, Kouzu K, Shinkawa H, et al.
Ann Gastroenterol Surg
. 2025 Mar;
9(2):369-378.
PMID: 40046532
Background: Appropriate antibiotic prophylaxis is essential for preventing surgical site infections (SSI); however, the clinical benefit of intraoperative redosing remains unclear and controversial owing to insufficient reliable evidence. Therefore, we...
2.
Hirai J, Hanai Y
J Infect Chemother
. 2025 Feb;
31(4):102668.
PMID: 40021002
Background: Ensitrelvir, a novel oral antiviral targeting the 3CL protease of SARS-CoV-2, has demonstrated efficacy in reducing viral load in clinical trials. Rapid viral clearance in healthcare workers (HCWs) with...
3.
Mori N, Shibata Y, Hirai J, Asai N, Mikamo H
J Infect Chemother
. 2025 Feb;
31(4):102650.
PMID: 39914651
Background: Broad-spectrum antibiotic use increases the risk of Clostridioides difficile infection (CDI), with recurrence rates varying by antibiotic type, spectrum, and treatment duration. We assessed CDI recurrence risk using the...
4.
Mori N, Nakamura A, Hirai J, Asai N, Shibata Y, Takayama M, et al.
Nagoya J Med Sci
. 2025 Jan;
86(4):683-692.
PMID: 39780922
() is known to cause intra-abdominal and anaerobic bloodstream infections. However, clinical insights and information on antimicrobial susceptibility in infections are limited. This study aimed to elucidate the clinical characteristics...
5.
Mori N, Shibata Y, Ohashi W, Hirai J, Asai N, Mikamo H
Cureus
. 2024 Nov;
16(10):e71984.
PMID: 39569238
Background: () bloodstream infection (SAB) remains a major clinical challenge despite appropriate antimicrobial therapy. Recent studies have suggested the potential benefits of P2Y12 inhibitors in SAB treatment, but controversy persists...
6.
Shibata Y, Hirai J, Mori N, Asai N, Hagihara M, Mikamo H
Antibiotics (Basel)
. 2024 Sep;
13(9).
PMID: 39334979
The present study aimed to evaluate the impact of prospective audit and feedback (PAF) on the use of inpatient broad-spectrum antibiotics for more than 10 days using days of therapy...
7.
Shibata Y, Hirai J, Mori N, Asai N, Hagihara M, Yamada Y, et al.
J Infect Chemother
. 2024 Sep;
31(1):102525.
PMID: 39303781
A previous study reported that the incidence of hyponatremia after linezolid (LZD) use was higher than that with vancomycin (VCM) use in adults. However, hyponatremia due to LZD in neonates...
8.
Asai N, Shibata Y, Yamada A, Ohashi W, Takayama M, Kawamoto Y, et al.
J Infect Chemother
. 2024 May;
30(11):1156-1161.
PMID: 38782237
Introduction: While respiratory syncytial virus (RSV) is one of the most common pathogens in adults admitted to the ICU due to respiratory diseases, no reports regarding the occurrence rate of...
9.
Shibata Y, Asai N, Hirai J, Mori N, Hagihara M, Mikamo H
J Infect Chemother
. 2024 May;
30(11):1141-1146.
PMID: 38729565
Background: Since the appropriate antibiotic duration for uncomplicated Staphylococcus aureus (S. aureus) bacteremia (u-SAB) in an immunocompromised state is still unclear, physicians are likely to extend antibiotic therapy from 2...
10.
Umemura T, Kato H, Asai N, Hagihara M, Hirai J, Yamagishi Y, et al.
Heliyon
. 2024 Apr;
10(8):e29811.
PMID: 38681574
Objectives: We performed a comprehensive systematic review and meta-analysis to evaluate the clinical or microbiological outcomes and safety of a combination of daptomycin (DAP) and β-lactams compared to DAP monotherapy...